Snorc is a novel cartilage specific small membrane proteoglycan expressed in differentiating and articular chondrocytes

Heinonen, J., Taipaleenmaki, H., Roering, P., Takatalo, M., Harkness, L., Sandholm, J., Uusitalo-Jarvinen, H., Kassem, M., Kiviranta, I., Laitala-Leinonen, T. and Saamanen, A. -M. (2011) Snorc is a novel cartilage specific small membrane proteoglycan expressed in differentiating and articular chondrocytes. Osteoarthritis and Cartilage, 19 8: 1026-1035. doi:10.1016/j.joca.2011.04.016


Author Heinonen, J.
Taipaleenmaki, H.
Roering, P.
Takatalo, M.
Harkness, L.
Sandholm, J.
Uusitalo-Jarvinen, H.
Kassem, M.
Kiviranta, I.
Laitala-Leinonen, T.
Saamanen, A. -M.
Title Snorc is a novel cartilage specific small membrane proteoglycan expressed in differentiating and articular chondrocytes
Journal name Osteoarthritis and Cartilage   Check publisher's open access policy
ISSN 1063-4584
1522-9653
Publication date 2011
Year available 2011
Sub-type Article (original research)
DOI 10.1016/j.joca.2011.04.016
Volume 19
Issue 8
Start page 1026
End page 1035
Total pages 10
Place of publication Camden, London, United Kingdom
Publisher Elsevier
Language eng
Abstract Objective: Maintenance of chondrocyte phenotype is a major issue in prevention of degeneration and repair of articular cartilage. Although the critical pathways in chondrocyte maturation and homeostasis have been revealed, the in-depth understanding is deficient and novel modifying components and interaction partners are still likely to be discovered. Our focus in this study was to characterize a novel cartilage specific gene that was identified in mouse limb cartilage during embryonic development. Methods: Open access bioinformatics tools and databases were used to characterize the gene, predicted protein and orthologs in vertebrate species. Immunohistochemistry and mRNA expression methodology were used to study tissue specific expression. Fracture callus and limb bud micromass culture were utilized to study the effects of BMP-2 during experimental chondrogenesis. Fusion protein with C-terminal HA-tag was expressed in Cos7 cells, and the cell lysate was studied for putative glycosaminoglycan attachment by digestion with chondroitinase ABC and Western blotting. Results: The predicted molecule is a small, 121 amino acids long type I single-pass transmembrane chondroitin sulfate proteoglycan, that contains ER signal peptide, lumenal/extracellular domain with several threonines/serines prone to O-N-acetylgalactosamine modification, and a cytoplasmic tail with a Yin-Yang site prone to phosphorylation or O-N-acetylglucosamine modification. It is highly conserved in mammals with orthologs in all vertebrate subgroups. Cartilage specific expression was highest in proliferating and prehypertrophic zones during development, and in adult articular cartilage, expression was restricted to the uncalcified zone, including chondrocyte clusters in human osteoarthritic cartilage. Studies with experimental chondrogenesis models demonstrated similar expression profiles with Sox9, Acan and Col2a1 and up-regulation by BMP-2. Based on its cartilage specific expression, the molecule was named Snorc, (Small NOvel Rich in Cartilage). Conclusion: A novel cartilage specific molecule was identified which marks the differentiating chondrocytes and adult articular chondrocytes with possible functions associated with development and maintenance of chondrocyte phenotype.
Keyword Articular cartilage
Cartilage specific
Chondrogenesis
Chondroitin sulfate
Novel gene
Transmembrane proteoglycan
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: Australian Institute for Bioengineering and Nanotechnology Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 2 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 23 Sep 2015, 15:22:10 EST by Linda Harkness on behalf of Aust Institute for Bioengineering & Nanotechnology